Format

Send to

Choose Destination
Nat Struct Mol Biol. 2010 Feb;17(2):248-50. doi: 10.1038/nsmb.1723. Epub 2010 Jan 24.

Structural basis of respiratory syncytial virus neutralization by motavizumab.

Author information

1
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Abstract

Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.

PMID:
20098425
PMCID:
PMC3050594
DOI:
10.1038/nsmb.1723
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center